Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma?

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 510–511 (2007)Cite this article

boxed-textHeemstra KA et al. (2007) Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 66: 58–64

Minimally detectable serum thyroglobulin levels obtained during longitudinal follow-up might detect evidence of residual disease, but they are not a reliable predictor of eventual death from differentiated thyroid carcinoma

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cooper DS et al. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 109–142

    Article  Google Scholar 

  2. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89–95

  3. Fleming TR and DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125: 605–613

    Article  CAS  Google Scholar 

  4. Smallridge RC et al. (2007) Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 92: 82–87

    Article  CAS  Google Scholar 

  5. Kloos RT and Mazzaferri EL (2005) A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90: 5047–5057

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Room FC3.3062, 1400 Holcombe Boulevard, Houston, TX 77030-4008, USA sisherma@mdanderson.org

Authors and Affiliations

  1. SI Sherman is Professor and Chair of the Department of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center, Houston, TX, USA.,

    Steven I Sherman

Authors
  1. Steven I Sherman
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sherman, S. Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma?. Nat Rev Endocrinol 3, 510–511 (2007). https://doi.org/10.1038/ncpendmet0532

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpendmet0532

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing